Antibody response to three-dose anti-SARS-CoV-2 mRNA-vaccination in treated solid cancer patients
Articolo
Data di Pubblicazione:
2024
Citazione:
Antibody response to three-dose anti-SARS-CoV-2 mRNA-vaccination in treated solid cancer patients / D. Dalu, M. Tarkowski, L. Ruggieri, M.S. Cona, A. Gabrieli, D. De Francesco, C. Fasola, S. Ferrario, A. Gambaro, E. Masedu, G. Parma, E. Rulli, C. De Stradis, D. Mavilio, F. Calcaterra, F. Manoni, A. Riva, N. La Verde. - In: INTERNATIONAL JOURNAL OF CANCER. - ISSN 1097-0215. - 154:8(2024 Apr 15), pp. 1371-1376. [10.1002/ijc.34817]
Abstract:
Solid cancer patients are at higher risk of SARS-CoV-2 infection and severe complications. Moreover, vaccine-induced antibody response is impaired in patients on anticancer treatment. In this retrospective, observational, hypothesis-generating, cohort study, we assessed the antibody response to the third dose of mRNA vaccine in a convenience sample of patients on anticancer treatment, comparing it to that of the primary two-dose cycle. Among 99 patients included, 62.6% were >= 60 years old, 32.3% males, 67.7% with advanced disease. Exactly 40.4% were receiving biological therapy, 16.2% chemotherapy only and 7.1% both treatments. After the third dose, seroconversion rate seems to increase significantly, especially in non-responders to two doses. Heterologous vaccine-type regimen (two-dose mRNA-1273 and subsequent tozinameran or vice versa) results in higher antibody levels. This explorative study suggests that repeated doses of mRNA-vaccines could be associated with a better antibody response in this population. Furthermore, heterologous vaccine-type three-dose vaccination seems more effective in this population. Since this is a hypothesis-generating study, adequately statistically powered studies should validate these results.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
COVID-19; cancer; immunogenicity; third dose; vaccine
Elenco autori:
D. Dalu, M. Tarkowski, L. Ruggieri, M.S. Cona, A. Gabrieli, D. De Francesco, C. Fasola, S. Ferrario, A. Gambaro, E. Masedu, G. Parma, E. Rulli, C. De Stradis, D. Mavilio, F. Calcaterra, F. Manoni, A. Riva, N. La Verde
Link alla scheda completa: